NATURAL INHIBITOR OF TRANSFORMING GROWTH-FACTOR-BETA PROTECTS AGAINST SCARRING IN EXPERIMENTAL KIDNEY-DISEASE

被引:956
作者
BORDER, WA
NOBLE, NA
YAMAMOTO, T
HARPER, JR
YAMAGUCHI, Y
PIERSCHBACHER, MD
RUOSLAHTI, E
机构
[1] TELIOS PHARMACEUT INC,SAN DIEGO,CA 92121
[2] LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037
关键词
D O I
10.1038/360361a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
THE central pathological feature of human kidney disease that leads to kidney failure is the accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth factor-beta (TGF-beta) underlies the accumulation of pathological matrix in experimental glomerulonephritis1. Administration of an antibody raised against TGF-beta to glomerulonephritic rats suppresses glomerular matrix production and prevents matrix accumulation in the injured glomeruli2. One of the matrix components induced by TGF-beta, the proteoglycan decorin, can bind TGF-beta and neutralize its biological activity3, so decorin may be a natural regulator of TGF-beta (refs 3, 4). We tested whether decorin could antagonize the action of TGF-beta in vivo using the experimental glomerulonephritis model1. We report here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming our hypothesis. On the basis of our results, decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-beta.
引用
收藏
页码:361 / 364
页数:4
相关论文
共 16 条
[1]   TRANSFORMING GROWTH-FACTOR BETA-REGULATES THE LEVELS OF DIFFERENT FIBRONECTIN ISOFORMS IN NORMAL HUMAN CULTURED FIBROBLASTS [J].
BALZA, E ;
BORSI, L ;
ALLEMANNI, G ;
ZARDI, L .
FEBS LETTERS, 1988, 228 (01) :42-44
[2]   DISTINGUISHING MINIMAL-CHANGE DISEASE FROM MESANGIAL DISORDERS [J].
BORDER, WA .
KIDNEY INTERNATIONAL, 1988, 34 (03) :419-434
[3]   SUPPRESSION OF EXPERIMENTAL GLOMERULONEPHRITIS BY ANTISERUM AGAINST TRANSFORMING GROWTH FACTOR-BETA-1 [J].
BORDER, WA ;
OKUDA, S ;
LANGUINO, LR ;
SPORN, MB ;
RUOSLAHTI, E .
NATURE, 1990, 346 (6282) :371-374
[4]  
BORDER WA, 1990, KIDNEY INT, V37, P289
[5]  
CHOI HU, 1989, J BIOL CHEM, V264, P2876
[6]   CORRELATION OF FIBROSIS AND TRANSFORMING GROWTH FACTOR-BETA TYPE-2 LEVELS IN THE EYE [J].
CONNOR, TB ;
ROBERTS, AB ;
SPORN, MB ;
DANIELPOUR, D ;
DART, LL ;
MICHELS, RG ;
DEBUSTROS, S ;
ENGER, C ;
KATO, H ;
LANSING, M ;
HAYASHI, H ;
GLASER, BM .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (05) :1661-1666
[7]   FIBRONECTIN LOCALIZATION IN THE RAT GLOMERULUS [J].
COURTOY, PJ ;
KANWAR, YS ;
HYNES, RO ;
FARQUHAR, MG .
JOURNAL OF CELL BIOLOGY, 1980, 87 (03) :691-696
[8]   COMPARATIVE DISTRIBUTION OF LAMININ, TYPE-IV COLLAGEN, AND FIBRONECTIN IN THE RAT GLOMERULUS [J].
COURTOY, PJ ;
TIMPL, R ;
FARQUHAR, MG .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1982, 30 (09) :874-886
[9]  
GINSBERG JM, 1992, J CLIN INVEST, V90, P1
[10]   COLOCALIZATION OF TRANSFORMING GROWTH FACTOR-BETA-2 WITH ALPHA-1(I) PROCOLLAGEN MESSENGER-RNA IN TISSUE-SECTIONS OF PATIENTS WITH SYSTEMIC-SCLEROSIS [J].
KULOZIK, M ;
HOGG, A ;
LANKATBUTTGEREIT, B ;
KRIEG, T .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (03) :917-922